Questcor to Provide Q1 Results
April 22 2008 - 9:30AM
Business Wire
Questcor Pharmaceuticals, Inc. (AMEX:QSC) announced today that it
will release financial results for the first quarter of fiscal 2008
ended March 31, 2008, before the market opens on Wednesday, April
30, 2008. The company will host a conference call to discuss these
results on Wednesday, April 30, 2008 at 11:00 a.m. ET. During this
call the company will discuss it first quarter 2008 results. Don
Bailey, President and Chief Executive Officer and Steve Cartt,
Executive Vice President, Corporate Development will host the call.
To participate in the live call by telephone, please dial (800)
257-7087 from the U.S. or (303) 262-2140 from outside the U.S.
Please use conference ID number 11113031#. Participants are asked
to call the above numbers 5-10 minutes prior to the starting time.
The call will also be webcast live at www.questcor.com. An audio
replay of the call will be available for 7 days following the call
at (800) 405-2236 for U.S. callers or (303) 590-3000 for those
calling outside the U.S. The password required to access the replay
is 11113031#. An archived webcast will also be available at
www.questcor.com for 90 days. About Questcor - Questcor
Pharmaceuticals, Inc. is a pharmaceutical company that owns two
commercial products, H.P. Acthar � Gel (�Acthar�) and Doral � , and
is developing new medications using strategies that generally
require lower capital investment when compared to traditional
development programs. Acthar (repository corticotropin injection)
is an injectable drug that is approved for the treatment of certain
disorders with an inflammatory component, including the treatment
of exacerbations associated with multiple sclerosis (�MS�). In
addition, Acthar is not indicated for, but is used in treating
patients with infantile spasms (�IS�), a rare form of refractory
childhood epilepsy, and opsoclonus myoclonus syndrome, a rare
autoimmune-related childhood neurological disorder. Doral is
indicated for the treatment of insomnia characterized by difficulty
in falling asleep, frequent nocturnal awakenings, and/or early
morning awakenings. The Company is also developing new medications,
including QSC-001, a unique orally disintegrating tablet
formulation of hydrocodone bitartrate and acetaminophen for the
treatment of moderate to moderately severe pain. For more
information, please visit www.questcor.com.
Questor (AMEX:QSC)
Historical Stock Chart
From Apr 2024 to May 2024
Questor (AMEX:QSC)
Historical Stock Chart
From May 2023 to May 2024